SOC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SOC is not a good buy right now. The stock is in a clear downtrend (bearish moving averages and deteriorating MACD), it’s trading just above key support (~9.71), and the latest news flow is dominated by a high-impact legal challenge (California AG lawsuit) that can delay/derail the restart narrative and keep volatility elevated. While options positioning leans bullish (put/call < 1) and Street analysts remain positive with high targets, the near-term tape + event risk is unfavorable for an impatient buyer.
Intellectia Proprietary Trading Signals
Trend is bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating persistent downward momentum. MACD histogram is negative (-0.273) and expanding lower, signaling increasing bearish momentum. RSI(6) at ~37 is not yet deeply oversold, so downside can continue before a technical mean reversion becomes compelling.
Key levels: Price 9.77 is sitting just above S1 support (9.714). A clean break below 9.71 increases the probability of a move toward S2 (8.815). Overhead resistance is heavy: pivot ~11.17, then R1 ~12.63. From a trader’s perspective, the stock would need to reclaim and hold above ~11.17 to argue the downtrend is stabilizing.
Regulatory progress narrative remains alive: prior PHMSA approval of restart plans for Lines 324/325 was a key milestone.
If federal positioning remains supportive, the market can quickly reprice restart timing and cash-flow potential.
Options market positioning (call-leaning put/call ratios) can amplify upside on any favorable legal/regulatory update.
Pattern-based projection in the dataset suggests a modestly positive 1-month skew (+6.22%), though this is secondary to the legal catalyst.
Primary near-term overhang: California Attorney General lawsuit challenging the pipeline restart/federal jurisdiction—directly threatens timing and certainty of the core catalyst.
“Cash crisis” concerns cited in news; uncertainty around funding runway can pressure shares and increase dilution risk.
Technical downtrend is intact; price is near support (~9.71). A breakdown can trigger another leg lower toward ~8.
Extremely high implied volatility signals the market expects large moves; without a positive catalyst, this often resolves lower in weak charts.
Latest reported quarter: 2025/Q3. Financials show the business is still loss-making and worsening YoY: Net income fell to -$110.38M (-56.81% YoY) and EPS declined to -1.11 (-72.99% YoY). Reported revenue and gross margin are shown as 0 (flat YoY), consistent with a company still in a pre/limited production phase where the equity story hinges on a successful restart. Bottom line: fundamentals are currently dominated by restart execution rather than operating growth trends.
Street view is bullish but has become more cautious around financing/dilution and legal timing. Recent notes show multiple Buys maintained (Benchmark Buy $20; Jefferies Buy $19–$20; Roth Buy $22), but price targets were cut materially after the $250M share placement (e.g., Jefferies $38 -> $20; Roth $26 -> $22), reflecting dilution and higher uncertainty.
Wall Street pros: (a) restart progress/regulatory milestones (PHMSA), (b) large upside to targets if production restarts, (c) perceived federal support tailwind. Wall Street cons: (a) injunction/legal risk and timing uncertainty, (b) funding/dilution overhang, (c) high volatility and binary outcomes.
